Clin2
NCT06204614Possibly a fitEnrolling by invitation

Drug screening for bladder cancer before surgery

Muscle Invasive Bladder Urothelial Carcinoma

Treatments studied

Part of Cancer, Kidney & urinary clinical trials.

This trial tests a tiny device placed into bladder tumors before surgery to see which drugs might work best for each patient, helping guide future treatment choices.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
18 people
Ages
18 years to 120 years
Study type
Interventional

Who can take part

  • You have bladder cancer that has spread into the muscle layer but not to lymph nodes (stage T2-T3 N0)
  • You are scheduled to have your bladder removed (cystectomy) as part of your care
  • Your tumor is at least 1 cm in size so the device can be placed
  • You are 18 years or older
  • You are willing to have a small device implanted in your tumor and then removed during surgery
  • You agree to genetic testing of your tumor and normal cells and to share de-identified data

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06257017Recruiting· Phase 2
Using DNA tests to guide chemotherapy after bladder cancer surgery

This trial checks if a DNA blood test can help decide who needs extra chemo after bladder or upper urinary tract cancer surgery. It tests whether watching for cancer DNA in the blood can match patients to the right treatment.

Hong Kong, Hong Kong
NCT06396533Recruiting
Improving cancer staging before bladder removal surgery

This trial tests if adding a special CT scan before bladder removal helps find muscle-invasive bladder cancer earlier. It includes people with different stages of bladder cancer who are planning to have their bladder removed.

Omaha, Nebraska
NCT07332351Not yet recruiting· Phase 2
Gene therapy, chemo, and immunotherapy before bladder cancer surgery

This trial tests a new treatment combination before bladder removal surgery for muscle-invasive bladder cancer. It uses a special virus-delivered gene therapy (nadofaragene firadenovec) plus two chemotherapy drugs (cisplatin and gemcitabine) and an immunotherapy drug (durvalumab) to try to shrink the tumor and improve outcomes.

Seattle, Washington
NCT05987241Recruiting· Phase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery

This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.

Phoenix, Arizona
NCT05394337Recruiting· Phase 1/Phase 2
Immunotherapy before bladder surgery for cisplatin-ineligible patients

This trial tests two immunotherapy drugs given before bladder/urinary tract cancer surgery. It aims to shrink the tumor and improve outcomes in people who cannot safely take cisplatin chemotherapy.

Houston, Texas
NCT07690878Not yet recruiting· Phase 2
PTC-guided therapy before bladder cancer surgery

This trial tests whether using a patient's own tumor cells in lab-made clusters (PTCs) can help guide chemotherapy before bladder removal surgery for muscle-invasive bladder cancer. If you qualify, you'll receive personalized treatment followed by surgery.

Nanjing, Jiangsu

Hear when a new Muscle Invasive Bladder Urothelial Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.